Navigation Links
Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
Date:10/12/2010

AURORA, Ontario, Oct. 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47.   These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.  

The Company plans to conduct a Phase I study in the U.S. in patients with refractory solid tumors and a  Phase I/II, multi-arm safety and preliminary efficacy study in patients with stage III/IV non-small cell lung cancer in Poland.  It intends to use the findings from its GLP toxicology studies to complete the necessary protocol designs and other supportive documentation, as final steps in preparing its U.S. Phase I IND and its Polish Phase I/II CTA dossiers.  As a result of some delays in completing its GLP toxicology studies, Helix now expects these IND/CTA submissions to be made in its second rather than its first quarter of fiscal 2011.  

"We are very pleased to reach this important clinic-enabling milestone in our L-DOS47 development program," said John Docherty, Helix president and COO.  "Having completed these studies, Helix believes it now has a sufficient preclinical pharmacology and toxicology database to support human clinical testing with this important new drug candidate.  Helix is committed to completing these submissions as soon as possible, as it is no longer waiting for any further preclinical study findings before doing so."

About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.  Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new dr
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix Biopharma Closes $11.4 Million Private Placement
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
6. Helix BioPharma Announces Q1 2009 Financial Results
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Announces Q2 2009 Financial Results
11. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... led by George Washington University Professor Tianshu Li ... in small droplets is strongly size-dependent, an important ... The formation of ice at the nanoscale is ... also has important implications for climate research and ... from supercooled water is generally initiated by a ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 NANONEX ... nanoimprint solutions , today announced the successful delivery ... manufacturing system, the NX-M200B, to a major Japanese ... is a fully-automated, production-ready, advanced nanoimprint lithography tool ... of wafer and substrate sizes and types. Based ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... Feb. 12 MBF Healthcare,Acquisition Corp. (Amex: ... announced today that it and Critical Home Solutions,Holdings, ... therapy and specialty infusion services, are scheduled to ... Global Healthcare Services,Conference in New York, NY. On ...
... and Brain Tumor ... Treatment, SUNNYVALE, ... in the field of radiosurgery,today announced key clinical presentation highlights from the ... At this year,s CyberKnife Users, meeting eight presentations reported,on large scale ...
... 12 Keck Graduate Institute,(KGI) today announced that ... Organization (BIO), will discuss "The American,Health Care System ... Will,Innovate?" at the 7th Annual Simon Ramo Distinguished ... pm., "We are thoroughly delighted that Jim ...
Cached Biology Technology:MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference 3CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 2CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 3CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 4KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 2KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 3
(Date:5/21/2013)... at Chicago College of Medicine will study gender differences in ... energy source -- and how changes in fat metabolism play ... 4-year grant from the National Heart, Lung and Blood Institute. ... for energy. These changes may play a major role in ... and women, says E. Douglas Lewandowski, director of the UIC ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... is known about the effect of physical education (PE) ... University finds that increasing the amount of time that ... of obesity. , The study represents some of the ... youth obesity, and is forthcoming in the Journal ... of the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
... plants around the world will act in a warming ... how they respond to artificial warming. But a new ... in the timing of flowering and leafing four to ... species could change far more quickly than the experiments ...
... (Edmonton) Coelacanths, an ancient group of fishes once thought ... one of their modern relatives was caught off the ... another splash and University of Alberta researchers are responsible. ... fossils of a coelacanth that he says are so ...
... in the rat brain that play a role in ... discovery, which builds on the team,s previous findings, offers ... syndrome. The researchers previously identified patterns of brain ... for memory storage. The patterns sometimes represented where an ...
Cached Biology News:Experiments may understate plant responses to climate 2Experiments may understate plant responses to climate 3New coelacanth find rewrites history of the ancient fish 2Rats recall past to make daily decisions 2Rats recall past to make daily decisions 3
Proliferin (C-14)...
... power of your ValveBank system! Program ... a Macintosh computer using graphic 'click-and-drag' timebars. ... print out program listings, then download your ... simple step., EasyCode is used for programming ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... The Holten MaxiSafe 2010 Class ... most ergonomical working condition of comfort ... safety, efficiency and performance.,Refined operator, environment ... of both exhausted and recirculated air.,Bottom ...
Biology Products: